France's Poxel Q2 revenue rises on higher TWYMEEG royalties

Poxel SA

30/07/2026 20:41

Overview
France biopharma firm's Q2 revenue rose 23% yr/yr, driven by higher TWYMEEG royalties
TWYMEEG net sales in Japan grew 32% yr/yr, supporting royalty growth
Company postponed 2025 financial statements due to debt valuation complexities

Outlook
Sumitomo Pharma forecasts TWYMEEG net sales to exceed 10 bln yen in 2026 financial yr
Company expects moderate double-digit growth in TWYMEEG sales for 2026 financial yr
Poxel expects to receive 12% royalties on TWYMEEG net sales in 2026 financial yr

Result Drivers
TWYMEEG ROYALTIES - Q2 revenue growth was driven by higher royalties from TWYMEEG sales in Japan

Company press release: ID:nBw8vyw7da

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
 
EUR 1.24 mln
 

Reuters Recommended Reads
July 30 - France's Sanofi Q2 revenue rises 17.8%, beats estimates
July 28 - France's Novacyt H1 revenue rises on SCD acquisition
July 30 - Netherlands' Pharming Q2 revenue falls 3%, cuts 2026 outlook

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)